Introduction
Neuronal loss after injury or disease in the human brain is irreversible and often leads to functional impairments. In the literature, neural protection and axon regeneration are often conflated with neuroregeneration. In this Perspective, we use the term neuroregeneration to refer specifically to the regeneration of new neurons. Engrafting neural stem cells (NSCs) into the CNS has been the classic approach for stem cell therapy and neuroregeneration. Transplantation of fetal tissue into Parkinson's patients is a key example (Lindvall et al., 1988) . The use of human fetal tissue is limited as human embryonic stem cells face ethical issues (Thomson et al., 1998) . Recent advancement in the field of induced pluripotent stem cells (iPSCs) has opened a new era for cell replacement therapy Takahashi and Yamanaka, 2006) . For CNS repair, fibroblast cells and astroglial cells have been directly reprogrammed into neurons in cell cultures in vitro (see recent reviews by Ang and Wernig, 2014; Heinrich et al., 2015; Xu et al., 2015) . Despite this advance, transplanting externally reprogrammed cells into the CNS still faces the huge challenge of overcoming immunorejection and functional integration.
Several labs have recently pioneered in vivo reprogramming technology inside the brain and spinal cord by converting endogenous glial cells into functional neurons for CNS repair (Grande et al., 2013; Guo et al., 2014; Heinrich et al., 2014; Niu et al., 2013; Su et al., 2014; Torper et al., 2013) . While earlier studies modulated adult neurogenesis in the CNS by manipulating endogenous neuroprogenitor cells (Buffo et al., 2005; Heins et al., 2002; Lie et al., 2004; Lim and Alvarez-Buylla, 2016; Ohori et al., 2006) , it was not until recent years that a clear concept of ''direct in vivo reprogramming'' emerged as the conversion of reactive glial cells into functional neurons for brain repair. The concept of in vivo reprogramming is in part inspired by iPSC and transdifferentiation technologies that were initially developed in in vitro cultures. In vivo reprogramming in the CNS is largely based on the fact that glial cells react to injury and become proliferative and hypertrophic in response to neuronal injury. Such reactive glial cells are one of the most prevalent pathological hallmarks associated with a wide variety of neurological disorders. In this Perspective, we discuss the cutting-edge technologies that reprogram reactive glial cells into functional neurons in the CNS in vivo. To qualify as a viable approach for neural repair, the newly reprogrammed neurons have to survive long-term in the CNS, integrate into local and global neural circuits by forming proper synaptic connections with preexisting neurons, and ultimately restore lost neural functions. In this Perspective, we discuss both the advantages of this new emerging technology in the field of regenerative medicine as well as the challenges for using in vivo reprogramming in CNS repair.
Classical Approach for CNS Repair
Overcoming the Glial Inhibitory Effect to Promote Axon Regeneration Upon nerve injury, both neurons and glial cells may die or degenerate. Once killed, neurons will be lost permanently while glial cells can be activated by injury and divide to repopulate themselves. The injury-induced glial cells are called reactive glial cells, which facilitate the formation of a defensive barrier to prevent the spread of injury (Sofroniew, 2015) . Killing reactive glial cells often exacerbates CNS injury (Anderson et al., 2016; Faulkner et al., 2004) . That being said, reactive glial cells are a double-edge sword releasing not only neurotrophic factors but also neural inhibitory factors such as chondroitin sulfate proteoglycans (CSPGs), lipocalin-2, and other cytokines that inhibit axonal regeneration (Ferreira et al., 2015; Silver and Miller, 2004; Yiu and He, 2006) . Several strategies have been developed to either block inhibitory molecules within the lesion core or encourage intrinsic neurite outgrowth of severed axons (Cregg et al., 2014) . CSPGs and NOGO (a myelin-associated inhibitor) are two major inhibitory factors for axon regeneration. Reducing the activity of these factors promotes axonal regeneration in vivo (Alilain et al., 2011; Bradbury et al., 2002; GrandPré et al., 2002) . In addition, manipulating signaling pathways such as cAMP and PTEN can also help axon regeneration (Dergham et al., 2002; Neumann et al., 2002; Park et al., 2008; Qiu et al., 2002; Smith et al., 2009; Sun et al., 2011) . Despite the potential for axonal regeneration by manipulating both intrinsic and extrinsic factors, neuronal replacement in the aftermath of nerve injury remains a difficult task. Stem Cell Therapy One strategy for neuroregeneration is the use of endogenous neural stem cells (NSCs) to generate new neurons (Figure 1 ). Endogenous NSCs exist in the adult brains within discrete regions where the ''stemness'' of these cells is sustained by unique microenvironments known as stem cell niches (Ma et al., 2005; Shen et al., 2008) . The subventricular zone of the adult forebrain and subgranular zone of the hippocampus are the major niches that harbor NSCs in the mouse and human adult brains (Doetsch et al., 1999; Eriksson et al., 1998; Gage, 2000; Gage et al., 1998; Johansson et al., 1999; Lim and Alvarez-Buylla, 2016) . Upon injury or under disease conditions, NSC proliferation and neurogenesis can be promoted in these niches of the adult brain and directed toward the injury sites (Arvidsson et al., 2002; Ming and Song, 2011; Nakatomi et al., 2002; Parent et al., 2002) . The endogenously generated neurons can maturate and integrate into local circuits (Ming and Song, 2011; van Praag et al., 2002) , but the capacity for endogenous neurogenesis is limited and falls short of generating sufficient numbers of new neurons for injury repair (Bonfanti, 2016; Goldman, 2016 ).
An alternative approach for neuroregeneration is the transplantation of external stem cells into the CNS to produce new neurons (Figure 1 ). NSCs can be efficiently differentiated into neurons in cell culture, and transplanted into the CNS (Barker et The in vitro approaches include: (1) using somatic cells such as skin fibroblasts to first reprogram into stem cells and then differentiate into neurons; (2) using somatic cells to directly trans-differentiate into neurons; (3) isolating stem cells or progenitor cells and differentiating into neurons in culture. These in vitro differentiated neurons or progenitor cells need to be transplanted into the CNS for neural repair. The in vivo approaches include modulating endogenous neural stem cells and in vivo reprogramming of internal glial cells to generate new neurons.
2014; Tyson and Anderson, 2014) . The use of transplantable human cells for therapeutic purpose is limited. Human embryonic stem cells (ESCs) were established in the late 1990s (Thomson et al., 1998) , but their use in therapy has been hampered because of ethical issues. Despite the success of in vitro differentiation from human ESCs (Perrier et al., 2004; Zhang et al., 2001) , in vivo transplantation of human ESCs into the CNS has faced many challenges including the difficulty of differentiation into target neurons with high efficiency (Ronaghi et al., 2010) , with limited success reported so far . Furthermore, many studies required immunedeficient mice or the use of immune suppressors, creating challenges for translating this technique into effective therapies for patients already with serious illness and compromised immune systems.
iPSC Technology and Trans-differentiation In Vitro iPSC Technology Induced pluripotent stem cell (iPSC) technology has the advantage of overcoming the ethical and resource limitations of human ESCs. Using only four transcription factors (Oct4, Sox2, Klf4, and c-Myc), Yamanaka and colleagues demonstrated that both mouse and human skin fibroblast cells can be reprogrammed into pluripotent stem cells Takahashi and Yamanaka, 2006) . This milestone work ignited huge enthusiasm in the field of regenerative medicine because of the potential to reprogram a patient's own cells into stem cells and then differentiate them into a variety of target cells for cell replacement therapy (Figure 1 ). In addition to fibroblasts, iPSCs have been derived from a variety of cell types by combinations of transcription factors, microRNAs, and small molecules (De Los Angeles et al., 2015; Inoue et al., 2014; Xu et al., 2015) . Because iPSCs can be derived from a patient's own cells (Brennand et al., 2011; Marchetto et al., 2010; Wen et al., 2014) , there is the potential to reduce immunorejection after transplantation; however, further research is required to determine this possibility (Araki et al., 2013; Zhao et al., 2011 Zhao et al., , 2015a . Clinical trials using iPSC-based therapy have been initiated to treat a variety of diseases including neurological disorders such as retinal disease, Parkinson's disease, multiple sclerosis, and spinal cord injury (Hayashi et al., 2016; Lin et al., 2016; Nori et al., 2011; Okano and Yamanaka, 2014) . iPSC technology has suffered from some drawbacks as demonstrated by tumorigenesis after transplantation (Lee et al., 2013) , and careful evaluation is required before clinical applications are considered (Tsuji et al., 2010) .
Trans-differentiation in Cell Cultures
The idea to use transcription factors to reprogram somatic cells into stem cells has inspired scientists to find shortcuts for obtaining terminally differentiated cells directly from fibroblasts or other easily accessible cells without going through a stem cell stage. This direct reprogramming process is often referred to as ''trans-differentiation.'' In fact, trans-differentiation was first successfully demonstrated in 1987 when a single gene MyoD was reported to directly convert fibroblasts into myoblasts (Davis et al., 1987) . Today, skin fibroblast cells can be directly transdifferentiated into many cell types including cardiomyocytes and neurons (Sadahiro et al., 2015; Tanabe et al., 2015; Vierbuchen et al., 2010; Xu et al., 2015) (Figure 1 ). Besides fibroblast cells, cultured glial cells such as astrocytes, pericytes or NG2 glia have also been reprogrammed into functional neurons in vitro using neurogenic transcription factors (Blum et al., 2011; Heinrich et al., 2010 Heinrich et al., , 2015 Karow et al., 2012) . The advantage of trans-differentiated cells over iPSCs for cell-replacement therapy is to reduce the lengthy process of preparing iPSCs and the potential of tumorigenesis. The disadvantage of trans-differentiation compared to iPSCs is the difficulty of storage and longterm use after reprogramming. For CNS repair, whether the trans-differentiated neurons can integrate successfully into the neural circuit after transplantation still needs to be thoroughly evaluated, but a few successful examples have been reported (Goldman, 2016; Heinrich et al., 2015; Kim et al., 2011) .
The Emergence of In Vivo Reprogramming
While the majority of the current work on neuroregeneration still relies upon transplantation of external cultured cells, in vitro approaches are facing limitations and uncertainties after transplantation in vivo. It has been demonstrated that NSCs can be successfully differentiated into motor neurons in vitro; however, injection of stem cells into the spinal cord resulted in a limited number of neurons in vivo. Furthermore, many stem cells were immune rejected or remained at the undifferentiated stage (Lu et al., 2014; Sahni and Kessler, 2010; Steinbeck and Studer, 2015) . The use of an immune suppressor to prevent immune rejection is not ideal in human patients due to weakened immune systems and the potential for unwanted secondary infections. One way to overcome the limitation of transplanting cells from in vitro culture to in vivo organs is to conduct in vivo reprogramming directly. The in vivo reprogramming approach makes use of internal cells to regenerate target cells for tissue repair. This method is typically carried out through the use of viral injections that ectopically express transcription factors in a particular cell type that is to be reprogrammed into another target cell type. Compared to in vitro reprogramming followed by cell transplantation, in vivo reprogramming avoids the complications of cell culture conditions and the serious immunorejection problem associated with cell transplantation.
The first in vivo reprogramming work using transcription factors to change one cell type into another in adult animals was conducted in the pancreas (Zhou et al., 2008) . Melton and colleagues employed three transcription factors (Ngn3, Pdx1, and MafA) to successfully reprogram adult pancreatic exocrine cells into insulin-secreting b-cells. Reprogrammed b cells not only resemble the endogenous b cells morphologically, but also can partially rescue the hyperglycemia in diabetic mice through a moderate increase of the serum insulin level (Zhou et al., 2008) . Following this initial success, it has been reported that other non-insulin-secreting cells can also be reprogrammed in vivo into functional b cells by various transcription factors or cytokines (Baeyens et al., 2014; Chera et al., 2014; Collombat et al., 2009 ). Interestingly, a recent study suggests that hyperglycemia may inhibit in vivo reprogramming of exocrine cells into b cells (Cavelti-Weder et al., 2016) , which may explain why the in vivo reprogramming efficiency is not very high in diabetic animal models.
Following advances in in vivo reprogramming in the pancreas, it was soon reported that the mesoderm tissue in mouse embryos can be reprogrammed into cardiac tissue by transcription factors Gata4, Tbx5, and Baf60c (Takeuchi and Bruneau, 2009) . After this embryonic work, Srivastava and colleagues (Qian et al., 2012) used GATA4, Tbx5, and Mef2c, while Olson and colleagues (Song et al., 2012) used GATA4, Tbx5, Mef2c, plus Hand2 to successfully convert cardiac fibroblast cells into cardiac-like cells in adult mice. They both showed that such cardiac myocytes reprogrammed in vivo can fire action potentials and even improve cardiac function by decreasing the infarct size (Qian et al., 2012; Song et al., 2012) . Similar in vivo reprogramming work in the mouse heart has been repeated by several labs with similar or different transcription factors (Ieda et al., 2010; Li et al., 2015b; Nam et al., 2013; Protze et al., 2012; Sadahiro et al., 2015; Song et al., 2012) . Recent evidence indicates that in vivo reprogramming may be extended to the liver where myofibroblasts can be converted into hepatocytes to treat fibrosis (Rezvani et al., 2016; Song et al., 2016) .
In Vivo Reprogramming in the CNS Direct in vivo reprogramming in the nervous system has advanced rapidly in recent years. Many labs from around the world have joined the effort on in vivo reprogramming inside the brain and spinal cord to regenerate new neurons for tissue repair (Figure 1 ). The first symposium dedicated to in vivo reprogramming was held at the annual meeting of the Society for Neuroscience in 2014 in Washington DC , indicating a tremendous interest in this emerging technology. Direct In Vivo Reprogramming of Astrocytes into Functional Neurons Our lab has been among the few groups pioneering in vivo reprogramming in the CNS. In 2010, after failed attempts to generate functional neurons inside the adult mouse brain through transplantation of iPSC-derived neuroprogenitors, we decided to develop an in vivo reprogramming approach to convert endogenous glial cells into functional neurons for brain repair. The transcription factor neurogenin2 (Ngn2) had previously been demonstrated to convert cultured mouse astrocytes into neurons with high efficiency in vitro (Heinrich et al., 2010) . However, injecting retroviruses expressing Ngn2 into the adult mouse cortex resulted in few reprogrammed new neurons.
Research from other groups indicates that Ngn2 needs to be combined with other factors to be effective for in vivo reprogramming (Gascon et al., 2016; Grande et al., 2013) . This discrepancy highlights the fact that even highly efficient in vitro reprogramming may not be readily applicable to in vivo conditions.
Given the contrast between in vitro and in vivo reprogramming using Ngn2, further research examined other neural transcription factors that might promote in vivo reprogramming in the adult brain. One article by Gage and colleagues reported that NeuroD1 plays an important role in hippocampal adult neurogenesis (Kuwabara et al., 2009) . We reasoned that a transcription factor that is expressed in the adult brain might be more efficient for in vivo reprogramming and brain repair. Indeed, after injecting retroviruses expressing NeuroD1 into the adult mouse cortex after stab injury, our lab reprogrammed reactive glial cells into functional neurons at the injury site . The use of retroviruses allows for the targeting of reactive glial cells that are proliferative after brain injury. Retroviruses predominately express target genes in dividing cells, leaving non-dividing neurons or resting glial cells untouched. The NeuroD1-mediated reprogramming efficiency is very high, because most astrocytes (90%) infected by NeuroD1 retroviruses become neurons after 2 weeks of expression. Such high efficiency for in vivo reprogramming has not been achieved using other transcription factors or in other organs such as the pancreas or heart. That being said, the infection efficiency in in vivo settings is difficult to assay, because there is no boundary to determine the total number of cells. Brain slice recordings revealed that the NeuroD1-converted neurons functionally mature in about 1 month and form synaptic connections with pre-existing neurons , suggesting that these newly reprogrammed neurons have successfully integrated into brain circuits.
Besides NeuroD1-mediated direct in vivo reprogramming, a combination of transcription factors (Ascl1, Brn2, and Myt1l) convert fibroblast cells into neurons as well as astrocytes into neuron-like cells in the mouse brain (Torper et al., 2013) . Further work found that expression of Ascl1 alone in midbrain astrocytes can reprogram astrocytes into functional neurons in young animals (postnatal 12-16 days) . Ascl1 has also been shown to convert reactive astrocytes originating from the subventricular zone (SVZ) after stroke into neurons, although at low efficiency (Faiz et al., 2015) . Likewise, Ngn2 has been reported to reprogram astrocytes into neurons in the adult rat brains when combined with a high dose of growth factors (FGF2+EGF), although the reprogramming efficiency is low (Grande et al., 2013) . Recently, Gö tz and colleagues demonstrated that when Ngn2 is co-expressed with Bcl2, the astrocyte-neuron reprogramming efficiency is significantly increased (Gascon et al., 2016 ) (see Table 1 for summary). Interestingly, when comparing the transcriptional regulation of Ngn2 and Ascl1 in cultured astrocytes, NeuroD4 is identified as a common downstream effector (Masserdotti et al., 2015) . Unlike NeuroD1 , NeuroD4 requires an additional factor Insm1 to reprogram cultured astrocytes into neurons (Masserdotti et al., 2015) . It is foreseeable that more transcription factors will be identified to reprogram astrocytes into neurons both in vitro and in vivo.
Earlier studies on adult neurogenesis targeted internal proliferative cells, mainly adult neural stem cells, to generate new neurons (Bonfanti, 2016; Kempermann et al., 2004; Lim and AlvarezBuylla, 2016; Ming and Song, 2011) . This technique is different from the in vivo reprogramming strategy developed in recent years. Using adult neural stem cells to generate new neurons is a natural process similar to what occurs during brain development. Direct in vivo reprogramming in contrast targets terminally differentiated cells such as an astrocyte that cannot naturally become a neuron without a forced change. Another important difference is that adult neural stem cells are not ubiquitous in the brain and spinal cord. The proliferation rate for neural stem cells declines significantly in aging animals, whereas glial cells are present throughout the CNS and are not easily exhaustible in old animals. Adult neurogenesis alone often cannot generate sufficient number of neurons for neural repair, providing an opportunity for in vivo reprogramming to overcome this limitation.
Indirect Reprogramming of Astrocytes into Neurons through Neuroblasts
In addition to directly reprogramming glial cells into neurons, another approach is to mimic adult neurogenesis by de-differentiating glial cells into neuroblast cells. Neuroblasts are immature neural precursor cells capable of dividing. Zhang and colleagues first used Sox2, a transcription factor highly expressed in NSCs, to reprogram astrocytes in the mouse striatum into neuroblast cells (Niu et al., 2013) . These astrocyte-converted neuroblasts remained proliferative and were further differentiated into functional neurons by BDNF plus noggin or VPA (Niu et al., 2013) . In a recent study, it was found that ectopic expression of Sox2 converted striatal astrocytes into Ascl1-positive neuroprogenitor cells, which were further induced by VPA into calretinin-positive cells (Niu et al., 2015) . Following the success in the striatum, Zhang and colleagues further demonstrated that the astrocytes inside the adult mouse spinal cord can also be reprogrammed into neuroblasts by Sox2 and then differentiated into neuronal cells after treatment with VPA . Such a twostep approach, from astrocytes to neuroblasts and then to neurons, has the advantage of generating a large number of neuroblast cells that can persist for a long time inside the brain. The disadvantage is that the efficiency of differentiating neuroblasts into neurons inside the adult brain is not very high. Further research is required to determine whether different combinations of small molecules might improve this.
In Vivo Reprogramming NG2 Glia into Neurons
In addition to astrocytes, NG2 glia, also known as oligodendrocyte precursor cells (OPCs), have been converted into neurons in the adult mouse brain. Upon expressing NeuroD1 in NG2 glial cells under the NG2 promoter, NG2 cells inside the adult mouse cortex can be converted into neuronal cells . While the majority of NeuroD1-converted NG2 cells become glutamatergic neurons, a small proportion of NG2-converted neurons are GABAergic . Besides NeuroD1, expressing a combination of transcription factors including Ascl1, Lmx1a, and Nurr1 in NG2 cells in the mouse striatum can convert NG2 cells into functional GABAergic neurons (Table 1) , but not dopaminergic neurons (Torper et al., 2015) . This is somewhat surprising, as noted by the authors, because Nurr1 is critical for dopaminergic neuron differentiation (Kim et al., 2003) , and earlier work reported that the same factors can successfully convert cultured fibroblasts or astrocytes into dopaminergic neurons (Caiazzo et al., 2011; Torper et al., 2013) . This is another example illustrating the discrepancies between in vitro and in vivo reprogramming. Besides astrocytes and NG2 cells, we have also tried to convert microglia into neurons using NeuroD1 but did not succeed , leaving it as an active area of research as to whether microglia, which come from hematopoietic stem cells, can be reprogrammed into neurons in vivo. In addition to direct reprogramming, NG2 cells may also be reprogrammed into neuronal cells after ectopically expressing Sox2, but not Ascl1, during stab injury (Heinrich et al., 2014) . As noted by the authors in their discussion, these NG2-converted neurons were characterized as immature GABAergic neurons. Using in vivo reprogramming to generate specific subtypes of GABAergic neurons, such as parvalbumin neurons in the cortex or medium spiny neurons in the striatum, remains to be determined. Multiple laboratories have been able to reprogram NG2 cells into GABAergic neurons, suggesting that it is now possible to generate both glutamatergic and GABAergic neurons through in vivo reprogramming. Direct Conversion between Different Neuronal Subtypes Not only can glial cells be reprogrammed into neurons, but one type of neuron can be reprogrammed into another type of neuron. Ectopic expression of a transcription factor Fezf2, which is usually expressed in cortical layer V pyramidal neurons, can reprogram layer IV spiny neurons into neurons with layer V/VI properties (De la Rossa et al., 2013) . Similarly, ectopic expression of Fezf2 in cortical layer II/III neurons can reprogram them into layer V/VI neurons (Rouaux and Arlotta, 2013) , resembling the Fezf2-induced differentiation of striatal progenitor cells into cortical neurons (Rouaux and Arlotta, 2010) . Such inter-neuronal reprogramming can alter the excitation-inhibition ratio of a given neural circuit, raising both an interesting perspective and potential concern for neuron-neuron conversion (Lodato et al., 2015) . Unlike astrocyte-neuron reprogramming that can occur in the adult mouse brain, the cortical neuron-neuron reprogramming mainly occurs in embryonic or early postnatal brains, suggesting that Fezf2 is a powerful transcription factor during early brain development but may lose its regulatory effect when neurons mature. One exception appears to be in the retina, where adult rod cells can become cone-like cells after inactivating Nrl, a critical gene for rod cell development (Montana et al., 2013) . It will be interesting to test whether glial cells in the retina can be reprogrammed in vivo into cone-like cells to save the rod cells from being converted.
Chemical Reprogramming of Astrocytes into Neurons
Transcription factor-mediated in vivo reprogramming in the CNS is mostly carried out through viral infection. This method involves complicated neural surgery and stereotaxic injection of viruses into the brain or spinal cord. An alternative approach would be to develop a drug therapy to convert glial cells into neurons using small molecules that can be easily synthesized and are convenient to use by patients. It has been reported that fibroblast cells can be chemically reprogrammed into iPSCs (Hou et al., 2013; Zhao et al., 2015b) , hepatocytes (Zhu et al., 2014) , cardiomyocytes , NSCs (Cheng et al., 2014; Zhang et al., 2016) , and even neuronal cells (He et al., 2015; Hu et al., 2015; Li et al., 2015a) . However, from a therapeutic point of view, because fibroblasts are not resident cells inside the brain, the fibroblast-converted neurons have to be transplanted into the adult brain and then face the hurdle of immunorejection. Different from fibroblast conversion, we have developed a chemical reprogramming approach to convert cultured human astrocytes into functional neurons with a cocktail of small molecules . The use of human glial cells for chemical reprogramming has the potential to further develop in vivo reprogramming of brain internal glial cells into functional neurons. Using a defined combination of small molecules that are administered sequentially to the culture medium, we demonstrate that about 67% of human astrocytes can be chemically reprogrammed into functional neurons. Notably, the human astrocyte-converted neurons can survive at least 5 months in cell culture and display robust synchronous bursting activities, suggesting that these human neurons are fully functional . Mechanistically, the chemical reprogramming of astrocytes into neurons is mediated through both epigenetic and transcriptional regulation. In particular, small molecules can activate transcription factors such as NeuroD1, Ngn1/2, and Ascl1 within 1 week, which may in turn promote the reprogramming from astrocytes into neurons . Chemical reprogramming of human astrocytes into functional neurons is the first step toward a drug therapy to regenerate functional neurons from patients' endogenous glial cells.
Advantages of In Vivo Reprogramming for CNS Repair
In vivo reprogramming is an emerging new field in regenerative medicine research. This advance holds great promise for future therapy because of the unique approach of using internal cells, not external cells, for regeneration and repair. By targeting a patient's own internal cells, in vivo reprogramming opens a new path of internal regeneration that is common in the animal kingdom but largely lost in mammals. Neuroregeneration in the brain and spinal cord is particularly difficult when compared to other organs such as the liver and skin. While neural injury such as stroke does induce some newborn neurons possibly through modulating adult neuroprogenitors, the number of new neurons is far less than the number of lost neurons, making self-repair in mammalian CNS very difficult. Stem cell therapy illustrates the challenges of using external cells for CNS repair.
In contrast, in vivo reprogramming makes use of internal cells that are adjacent to the lost cells to regenerate new cells for replacement. The immediate and perhaps the most important advantage of such internal cell conversion is to avoid immunorejection caused by external cell transplantation (see Table 2 for comparison between in vivo reprogramming and cell transplantation). For CNS repair, it is a necessary step to generate sufficient numbers of functional neurons for repair. As discussed above, the in vivo reprogramming efficiency in the brain and spinal cord can range from low (<20%), medium (20%-50%), and high (>50%), with NeuroD1-mediated reprogramming the highest (90%) (see Table 1 ). We predict that any in vivo reprogramming with >50% efficiency should have significant impact on repairing tissue but more research is needed. It remains to be tested whether variable levels of reprogramming will have any impact on functional recovery.
The second advantage of in vivo reprogramming is the capacity to regenerate new cells right at the injury sites using neighboring cells. Minimal interference from outside the injury site is the most economic recovery mechanism. Besides local environmental cues, the intrinsic lineage of the neighboring cells at a specific region may be a critical factor for the cell's identity after in vivo reprogramming. In the CNS, for example, astrocytes in the mouse cortex are different from their counterparts in the striatum in terms of reprogrammability and neuronal identity despite expressing the same transcription factors (Grande et al., 2013; Niu et al., 2013) . Such subtle regional differences in intrinsic cell lineage may be too difficult to closely mimic in a petri dish.
The third advantage of in vivo reprogramming is targeting proliferative cells. After reprogramming, the original source cells can still divide to regenerate themselves. For most organs in the human body, there are often certain cell types that can be activated by injury and start to proliferate for wound healing. The proliferative cells involved in injury are an ideal source for in vivo reprogramming as they are theoretically inexhaustible unless depleted under extreme circumstances. With the rapid development of trans-differentiation technology, it is now possible to reprogram almost any type of cell into another type of cell in culture. For therapeutic purposes, it is not desirable to reprogram a terminally differentiated cell that is not capable of proliferation. Instead, an ideal strategy for in vivo reprogramming is to reprogram cells that can divide and regenerate themselves. The reactive glial cells that are present after stab injury have been frequently used to regenerate functional neurons due to their capacity to divide and generate new glial cells. In a mouse model for Alzheimer's disease (AD) at 14 months, the reactive glial cells that surround amyloid plaques in the mouse cortex can still be efficiently reprogrammed into functional neurons . Besides AD, reactive glial cells are also associated with a wide array of neurological disorders such as Parkinson's disease and ALS. Successful in vivo reprogramming in the AD mouse model may provide an important alternative approach for treating neurodegenerative disorders. It is important to point out that, while previous studies on modulating adult neurogenesis to treat AD may share certain similarities with in vivo reprogramming, endogenous neural stem cells in the adult brain are limited whereas glia are more ubiquitous.
Using in vivo reprogramming to convert reactive glial cells into functional neurons is not equal to killing or removing reactive glial cells in the CNS. In fact, these two approaches are drastically different and will likely lead to two completely opposite outcomes (Figure 2 ). Although reactive glial cells are critical for forming a defense barrier to limit the detrimental effect following the initial neural injury, a long-term glial scar tissue that is lacking functional neurons will not be helpful for brain or spinal cord functional recovery. Deleting reactive glial cells before scar formation will deprive the beneficial effects of reactive glial cells and can worsen a nerve injury (Anderson et al., 2016; Sofroniew, 2015) (Figure 2 ). For in vivo reprogramming to be more effective, the ideal time window will likely be after the original scar has formed and reactive glia have contained the injury. The hope for reprogramming reactive glial cells into functional neurons will be to reverse the glial scar back to neural tissue and eventually restore the lost neural functions (Figure 2 ). The key difference between killing reactive glial cells versus reprogramming reactive glial cells is that the killing approach does not generate new neurons, whereas reprogramming can.
It should be pointed out that only a fraction of the reactive glial cells will be reprogrammed into functional neurons, leaving the remaining reactive glial cells with their proliferative capability. Even after in vivo reprogramming, the scar tissue will not be a collection of neurons without glial cells. Rebalancing the neuron-glia ratio after injury is important for CNS repair and is an area of active further research. (Grande et al., 2013) . Another method for enhancing neuronal survival is to co-express reprogramming factors together with anti-apoptotic factors such as Bcl2 (Gascon et al., 2016) . A second major challenge for in vivo reprogramming is the regeneration of specific subtypes of neurons that are lost during injury or disease. In vivo reprogramming with NeuroD1 or Ngn2 plus Bcl2 can regenerate glutamatergic neurons, the major neuronal subtype in the mouse brain (Gascon et al., 2016; Guo et al., 2014) . In addition, GABAergic neurons have also been reprogrammed in vivo Heinrich et al., 2014; Torper et al., 2015) . Together, glutamatergic and GABAergic neurons account for more than 90% of the total neurons in the mammalian brain. Attempts to reprogram dopaminergic neurons in vivo have not been successful. Specific subtypes of GABAergic neurons such as parvalbumin neurons have not yet been generated. The field of in vivo reprogramming is attempting to generate a multitude of neuronal subtypes including cholin- In vivo reprogramming is a constructive strategy to regenerate functional neurons out of reactive glial cells, whereas killing reactive glial cells is a destructive process. ergic, serotonergic, and norepinephrinergic neurons. The technology has not yet been successful in this conversion. Generating specific subtypes of neurons is important for the treatments of specific diseases, such as dopaminergic neurons for Parkinson's disease.
The third challenge is rebuilding neural circuits after in vivo reprogramming. This hurdle is perhaps the most important one to overcome for in vivo reprogramming to be successful in future clinical applications. How can a newborn neuron send its axon to the right target? Is it possible for the newborn neurons to innervate the exact target that was innervated previously by the lost neurons? To answer this question, we need to step back and think about how a neuron establishes synaptic connections during brain or spinal cord development. Significant progress has been made in understanding how newborn neurons in the human brain navigate the complicated maze of billions of neurons to find their precise targets. The axon growth cones of pioneering neurons find their targets through cell adhesion molecules and interactions with local guidance cues, establishing pathways for later axons to follow (O'Donnell et al., 2009; Yam and Charron, 2013) .
The final and most important challenge is whether newly reprogrammed neurons can restore lost brain or spinal cord function caused by injury or disease. This will largely depend on how many functional neurons are generated, whether they are the right subtypes, and whether they can form synaptic connections with the right targets. Previous studies on modulating endogenous neuroprogenitor cells or transplantation of exogenous stem cells, neuroprogenitors, or neurons have generally produced an insufficient number of neurons for functional repair (Goldman, 2016) . By targeting endogenous glial cells, including both astrocytes and NG2 cells/OPCs, in vivo reprogramming can generate a sufficient number of functional neurons for CNS repair. In fact, the opposite challenge might arise for in vivo reprogramming: will too many glial cells be converted into neurons and result in epilepsy or other problems? While so far no published work has been able to generate more neurons than the lost ones through direct in vivo reprogramming, this is still a legitimate concern. Nevertheless, the solution may not be difficult: if too many neurons are generated under a specific dosage of virus or small molecules, reducing the dosage will reduce the number of reprogrammed neurons. The more challenging question is how to generate the correct ratio of different subtypes of neurons in a specific brain region. By controlling the composition of transcription factors, it is possible to generate different ratios of glutamatergic to GABAergic neurons. It should be noted that many of these challenges such as neuronal survival and circuit integration are not unique to in vivo reprogramming, but rather are commonly applicable to the entire field of CNS repair, regardless of the in vitro or in vivo approach that is adopted.
The challenges for in vivo reprogramming will also be different when considering clinical applications with virus-based gene therapy versus chemical-based drug therapy. It is foreseeable that if an injury is restricted to a local area, such as a focal stroke or a spinal cord injury, local injection of viral particles expressing NeuroD1 or other transcription factors may be able to regenerate new neurons and restore lost functions. However, for diseases involving large brain or spinal cord areas, such as Alzheimer's disease or ALS, it may not be practical to inject viral particles throughout the brain or spinal cord, unless intravenous injection of viral particles can reach CNS with high efficiency (Deverman et al., 2016) . Alternatively, small molecules may provide a more pragmatic approach to reach the brain or spinal cord widely and convert many glial cells into functional neurons over a large area. The biggest challenge for drug therapy is toxicity. The systemic administration of drugs, either orally or intravenously, must minimize the side effects on other organs such as the heart, liver, and kidney. Another major obstacle is how to make the drugs pass through the blood-brain barrier with high efficiency. While ultrasonic waves (Burgess et al., 2015) and some chemicals such as mannitol (Park et al., 2015) have been reported to open the blood-brain barrier, it has yet to be tested whether they are safe for in vivo chemical reprogramming. Even if drugs can reach the brain or spinal cord, they will need to act more specifically on glial cells, and ideally on reactive glial cells, without serious side effects on existing neurons or other cells. An additional challenge for drug therapy is that, unless a single chemical can do the job, the number of chemicals used for in vivo reprogramming should best be limited to a few chemicals to minimize the complications associated with toxicity, pharmacokinetics, and pharmacodynamics of each individual drug and all their combinations.
Concluding Remarks
In the past 3 years, we have witnessed rapid advances for a new technology with the potential to transform the CNS repair field through in vivo reprogramming internal glial cells into functional neurons. This has been achieved in both the brain and the spinal cord. By targeting both astrocytes and NG2 glia (OPCs), in vivo reprogramming has been successful in regenerating glutamatergic neurons as well as GABAergic neurons. In vivo reprogramming is still in its early stages, but the technology is already showing great promise for cell regeneration and tissue repair. While many people in the stem cell field are still working on in vitro stem cell differentiation before in vivo transplantation, scientists have increasingly realized the potential of in vivo reprogramming as an effective regeneration strategy. By targeting internal proliferative cells for direct in vivo reprogramming, many side effects associated with in vitro cell culture and transplantation are theoretically eliminated. While many challenges lie ahead to translate in vivo reprogramming into clinical therapies, none of these are insurmountable, and most of the challenges facing in vivo reprogramming will also be faced by other approaches, including stem cell therapy. For CNS repair, one has to demonstrate rebuilding of neural circuits after in vivo reprogramming and achieve functional recovery in animal models before attempting any human clinical trials. Nevertheless, for proof of concept, we have already demonstrated that cultured human astrocytes can be directly reprogrammed into functional neurons either by NeuroD1 expression or by small molecules Zhang et al., 2015) , suggesting that astrocyte-to-neuron conversion is potentially applicable to human patients. On the other hand, given the lessons we have learned on in vitro versus in vivo reprogramming, one should be cautious about interpreting success in vitro using cultured human glial cells. Considering the large gap between the mouse brain data in vivo and the human cell data in vitro, one potential bridge toward future clinical trials is a successful demonstration of functional improvement in non-human primate models through in vivo reprogramming.
